My Blue Dots – Page 44

Not all ‘forever chemicals’ are equal: Experts call for nuanced PFAS policy to protect public health and the environment

MyBlueDots2 months ago01 mins

The public, legislators, and media often group per- and polyfluoroalkyl substances, known as PFAS or “forever chemicals,” which are found globally in countless products, into a single category. While certain PFAS are harmful for human and public health, new articles in Heart Rhythm emphasize that fluoropolymers, a specific class of PFAS, are not considered environmental contaminants and are indispensable for use in medical devices. Experts call for a balanced approach to protect both the environment and availability of essential medical technologies.

New study finds sharp increase in nicotine pouch ingestions among young children

MyBlueDots2 months ago01 mins

A new study reveals that ingestions of nicotine pouches by young children have surged in recent years. Researchers at the Center for Injury Research and Policy of the Abigail Wexner Research Institute at Nationwide Children’s Hospital and the Central Ohio Poison Center analyzed calls to U.S. poison centers and found an alarming 763% increase in the rate of reported nicotine pouch ingestions among children younger than 6 years old from 2020 to 2023.

Supporting autistic patients in health care

MyBlueDots2 months ago01 mins

Caring for autistic patients requires a unique approach, and a new study published in the Canadian Medical Association Journal provides tips on looking after these patients.

Obesity rates in Canada increased after start of COVID-19 pandemic

MyBlueDots2 months ago01 mins

A new study published in theCanadian Medical Association Journal found obesity rates based on body mass index (BMI) increased faster in the four years after the start of the pandemic than in the previous 11 years, especially in younger adults.

MyBlueDots

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

MyBlueDots2 months ago01 mins

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society’s annual meeting (ENDO 2025). In the Phase 2b trial, avexitide 90 mg once daily, the dose being

Grandfather’s environmental chemical exposures may influence when girls get first period

MyBlueDots2 months ago01 mins

A grandfather’s exposure to endocrine-disrupting chemicals may impact the age when his granddaughter starts her first period, according to a study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.

AI-powered application enables clinicians to diagnose endocrine cancers faster and more accurately

MyBlueDots2 months ago01 mins

A novel artificial intelligence (AI) application capable of diagnosing endocrine cancers with speed and accuracy is being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.

Early-life exposure to endocrine-disrupting chemicals may fuel food preferences

MyBlueDots2 months ago01 mins

Exposure to endocrine-disrupting chemicals in early life, including during gestation and infancy, results in a higher preference for sugary and fatty foods later in life, according to an animal study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.

Age at woman’s first period can offer clues about long-term health risks

MyBlueDots2 months ago01 mins

The age at which a woman has her first period can offer valuable clues about her long-term risk for conditions like obesity, diabetes, heart disease and reproductive health issues, according to a study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.

Intermittent energy restriction may improve outcomes in people with obesity and type 2 diabetes

MyBlueDots2 months ago01 mins

Intermittent energy restriction, time-restricted eating and continuous energy restriction can all improve blood sugar levels and body weight in people with obesity and type 2 diabetes, according to a study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.

Useful _Links

Variables associated with heart failure compared for men and women

AI and lab tests combine to predict disease risk from rare genetic variants

Cancer survivors more likely to take Rx for mental health conditions

Mortality up for children with leukemia from lowest SES neighborhoods

Racing against antibiotic resistance: Scientists fear funding cuts will slow momentum

New study shows stress impacts heart at molecular level

Not all ‘forever chemicals’ are equal: Experts call for nuanced PFAS policy to protect public health and the environment

New study finds sharp increase in nicotine pouch ingestions among young children

Supporting autistic patients in health care

Obesity rates in Canada increased after start of COVID-19 pandemic

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Grandfather’s environmental chemical exposures may influence when girls get first period

AI-powered application enables clinicians to diagnose endocrine cancers faster and more accurately

Early-life exposure to endocrine-disrupting chemicals may fuel food preferences

Age at woman’s first period can offer clues about long-term health risks

Intermittent energy restriction may improve outcomes in people with obesity and type 2 diabetes

Useful Links

Useful _Links